Why speed and flexibility matter now more than ever
Posted: 20 October 2025 | | No comments yet
The balance between speed, scale, and compliance has never been more critical. As GLP-1s, biosimilars, and advanced therapies reshape global priorities, pharma leaders face a new question: how can manufacturing infrastructure evolve fast enough to keep pace?
The pharmaceutical industry is at a turning point. After years of moving toward specialized, small-batch therapies, the explosive rise of GLP-1s, biosimilars, and vaccines has reignited the need for large-scale, high-quality manufacturing. Yet, finding a CDMO partner that combines speed, flexibility, and unwavering compliance is more difficult than ever.
This whitepaper explores how forward-thinking CDMOs are transforming their operations to meet today’s demanding environment — and how ROIS is leading the way.
Key insights you’ll discover
- From niche to scale: How the GLP-1 boom is reshaping pharma manufacturing priorities
- The new compliance challenge: What evolving GMP standards – including Annex 1 revisions – mean for sterile production.
- Bridging speed and scale: Why most CDMOs can’t do both, and what separates the ones that can.
- Technology transfer at pace: Proven strategies to achieve first GMP batch in as little as nine months.
- Future-ready facilities: How modular design, cross-trained teams, and supply chain redundancy enable true agility.
- Compliance from day one: Why early regulatory focus minimizes risk and accelerates approval.
CLICK HERE TO ACCESS THE FULL ARTICLE (FREE DOWNLOAD)
Related topics
Biologics, Cell and Gene Therapy, Regulation & Legislation, Research & Development (R&D), Technology
